311 related articles for article (PubMed ID: 34258585)
1. Accelerating precision medicine in metastatic prostate cancer.
Mateo J; McKay R; Abida W; Aggarwal R; Alumkal J; Alva A; Feng F; Gao X; Graff J; Hussain M; Karzai F; Montgomery B; Oh W; Patel V; Rathkopf D; Rettig M; Schultz N; Smith M; Solit D; Sternberg C; Van Allen E; VanderWeele D; Vinson J; Soule HR; Chinnaiyan A; Small E; Simons JW; Dahut W; Miyahira AK; Beltran H
Nat Cancer; 2020 Nov; 1(11):1041-1053. PubMed ID: 34258585
[TBL] [Abstract][Full Text] [Related]
2. Future directions for precision oncology in prostate cancer.
Mizuno K; Beltran H
Prostate; 2022 Aug; 82 Suppl 1(Suppl 1):S86-S96. PubMed ID: 35657153
[TBL] [Abstract][Full Text] [Related]
3. Five-year downstream outcomes following prostate-specific antigen screening in older men.
Walter LC; Fung KZ; Kirby KA; Shi Y; Espaldon R; O'Brien S; Freedland SJ; Powell AA; Hoffman RM
JAMA Intern Med; 2013 May; 173(10):866-73. PubMed ID: 23588999
[TBL] [Abstract][Full Text] [Related]
4. Towards precision oncology in advanced prostate cancer.
Ku SY; Gleave ME; Beltran H
Nat Rev Urol; 2019 Nov; 16(11):645-654. PubMed ID: 31591549
[TBL] [Abstract][Full Text] [Related]
5. Precision medicine for advanced prostate cancer.
Mullane SA; Van Allen EM
Curr Opin Urol; 2016 May; 26(3):231-9. PubMed ID: 26909474
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option.
Mayor N; Sathianathen NJ; Buteau J; Koschel S; Antón Juanilla M; Kapoor J; Azad A; Hofman MS; Murphy DG
BJU Int; 2020 Nov; 126(5):525-535. PubMed ID: 32559353
[TBL] [Abstract][Full Text] [Related]
7. Moving Precision Oncology for Advanced Prostate Cancer from Theory to Practice.
Mateo J; Beltran H
Eur Urol Focus; 2023 Jan; 9(1):110-113. PubMed ID: 35999168
[TBL] [Abstract][Full Text] [Related]
8. Optimization of therapies for men with advanced prostate cancer: a review of recent developments with a look toward the future.
Gourdin T
Curr Opin Oncol; 2019 May; 31(3):188-193. PubMed ID: 30925537
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer patient stratification by molecular signatures in the Veterans Precision Oncology Data Commons.
Hernandez KM; Venkat A; Elbers DC; Bihn JR; Brophy MT; Do NV; La J; Liu Q; Prokhorenkov A; Metoki-Shlubsky N; Sung FC; Paller CJ; Fillmore NR; Grossman RL
Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 38050021
[TBL] [Abstract][Full Text] [Related]
10. PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.
Koshkin VS; Patel VG; Ali A; Bilen MA; Ravindranathan D; Park JJ; Kellezi O; Cieslik M; Shaya J; Cabal A; Brown L; Labriola M; Graham LS; Pritchard C; Tripathi A; Nusrat S; Barata P; Jang A; Chen SR; Garje R; Acharya L; Hwang C; Pilling A; Oh W; Jun T; Natesan D; Nguyen C; Kilari D; Pierro M; Thapa B; Cackowski F; Mack A; Heath E; Marshall CH; Tagawa ST; Halabi S; Schweizer MT; Armstrong A; Dorff T; Alva A; McKay R
Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):388-396. PubMed ID: 34363009
[TBL] [Abstract][Full Text] [Related]
11. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
12. Rate of change in investigational treatment options: An analysis of reports from a large precision oncology decision support effort.
Araya A; Zeng J; Johnson A; Shufean MA; Rodon J; Meric-Bernstam F; Bernstam EV
Int J Med Inform; 2020 Nov; 143():104261. PubMed ID: 32889387
[TBL] [Abstract][Full Text] [Related]
13. Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management.
Koo KM; Mainwaring PN; Tomlins SA; Trau M
Nat Rev Urol; 2019 May; 16(5):302-317. PubMed ID: 30962568
[TBL] [Abstract][Full Text] [Related]
14. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.
Radovich M; Kiel PJ; Nance SM; Niland EE; Parsley ME; Ferguson ME; Jiang G; Ammakkanavar NR; Einhorn LH; Cheng L; Nassiri M; Davidson DD; Rushing DA; Loehrer PJ; Pili R; Hanna N; Callaghan JT; Skaar TC; Helft PR; Shahda S; O'Neil BH; Schneider BP
Oncotarget; 2016 Aug; 7(35):56491-56500. PubMed ID: 27447854
[TBL] [Abstract][Full Text] [Related]
15. Challenging Standard-of-Care Paradigms in the Precision Oncology Era.
Subbiah V; Kurzrock R
Trends Cancer; 2018 Feb; 4(2):101-109. PubMed ID: 29458960
[TBL] [Abstract][Full Text] [Related]
16. Precision Oncology for Metastatic Prostate Cancer: Translation into Practice.
De Santis M; Mottet N; Cornford P; Gillessen S;
Eur Urol; 2020 Dec; 78(6):771-774. PubMed ID: 32863055
[TBL] [Abstract][Full Text] [Related]
17. PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment.
Thouvenin J; Van Marcke C; Decoster L; Raicevic G; Punie K; Vandenbulcke M; Salgado R; Van Valckenborgh E; Maes B; Joris S; Steichel DV; Vranken K; Jacobs S; Dedeurwaerdere F; Martens G; Devos H; Duhoux FP; Rasschaert M; Pauwels P; Geboes K; Collignon J; Tejpar S; Canon JL; Peeters M; Rutten A; Van de Mooter T; Vermeij J; Schrijvers D; Demey W; Lybaert W; Van Huysse J; Mebis J; Awada A; Claes KBM; Hebrant A; Van der Meulen J; Delafontaine B; Bempt IV; Maetens J; de Hemptinne M; Rottey S; Aftimos P; De Grève J
ESMO Open; 2022 Aug; 7(4):100524. PubMed ID: 35970014
[TBL] [Abstract][Full Text] [Related]
18. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.
Qaseem A; Barry MJ; Denberg TD; Owens DK; Shekelle P;
Ann Intern Med; 2013 May; 158(10):761-769. PubMed ID: 23567643
[TBL] [Abstract][Full Text] [Related]
19. Personalized strategies in population screening for prostate cancer.
Remmers S; Roobol MJ
Int J Cancer; 2020 Dec; 147(11):2977-2987. PubMed ID: 32394421
[TBL] [Abstract][Full Text] [Related]
20. Trade-Off between Treatment of Early Prostate Cancer and Incidence of Advanced Prostate Cancer in the Prostate Screening Era.
Shen X; Kumar P
J Urol; 2016 May; 195(5):1397-1402. PubMed ID: 26656266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
